A phase II study to evaluate the efficacy of regorafenib in C-KIT mutated metastatic malignant melanoma patients who have progressed on first-line treatment: A Multicenter Trial of Korean Cancer Study Group (UN-14–13)

Kim, K. H.; Lee, H.J.; Lee, S.J.; Kim, M.; Ahn, M.S.; Choi, M.Y.; Lee, N.R.; Jung, M.; Shin, S. J.

doi:10.1016/S0959-8049(22)01025-5

YUHSpace

BROWSE

0 472

Cited 0 times in

A phase II study to evaluate the efficacy of regorafenib in C-KIT mutated metastatic malignant melanoma patients who have progressed on first-line treatment: A Multicenter Trial of Korean Cancer Study Group (UN-14–13)

Authors: Kim, K. H. ; Lee, H.J. ; Lee, S.J. ; Kim, M. ; Ahn, M.S. ; Choi, M.Y. ; Lee, N.R. ; Jung, M. ; Shin, S. J.

Citation: European Journal of Cancer, Vol.174(Supppl 1) : S85-S86, 2022-10

Journal Title: EUROPEAN JOURNAL OF CANCER

ISSN: 0959-8049

Issue Date: 2022-10

DOI: 10.1016/S0959-8049(22)01025-5

Appears in Collections:: 7. Others (기타) > Others (기타) > 1. Journal Papers

Yonsei Authors: Shin, Sang Joon(신상준) https://orcid.org/0000-0001-5350-7241

URI: https://ir.ymlib.yonsei.ac.kr/handle/22282913/193863

사서에게 알리기

Show full item record Find it @ YMLIB

License

YUHSpace: A phase II study to evaluate the efficacy of regorafenib in C-KIT mutated metastatic malignant melanoma patients who have progressed on first-line treatment: A Multicenter Trial of Korean Cancer Study Group (UN-14–13)

YUHSpace

BROWSE

Browse

Links